Cite
HARVARD Citation
Plante, M. et al. (n.d.). 2022-RA-678-ESGO CONTESSA/NEOCON-F trial: Assessing the effectiveness and safety of neoadjuvant chemotherapy followed by fertility-sparing surgery in FIGO 2018 stage IB2 cervical cancer. International journal of gynecological cancer. p. A20. [Online].